Go Pro
NASDAQ:BIOA

BioAge Labs Q2 2026 Earnings Report

BioAge Labs logo
$7.05 -0.16 (-2.22%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$7.28 +0.23 (+3.26%)
As of 09/25/2026 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioAge Labs EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.65
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

BioAge Labs Revenue Results

Actual Revenue
$2.45 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioAge Labs Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Wednesday, August 5, 2026
Conference Call Time
7:00AM ET

BioAge Labs Earnings Headlines

Bioage Labs Inc (BIOA)
BioAge Labs to Present at Upcoming Investor Conferences
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Financial Comparison: BioAge Labs (BIOA) versus Its Competitors
See More BioAge Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioAge Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAge Labs and other key companies, straight to your email.

About BioAge Labs

BioAge Labs (NASDAQ:BIOA) (NASDAQ:BIOA) is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. Its research uses human longevity data and proprietary computational biology tools to identify pathways associated with aging-related diseases and to develop potential therapies aimed at extending healthy lifespan and improving physical function.

The company’s lead investigational program is azelaprag, also known as BGE-105, an oral small-molecule apelin receptor agonist being studied for its potential to preserve muscle mass and improve physical performance in older adults. BioAge is also evaluating its broader pipeline in areas such as obesity, metabolic disease, muscle health and immune function, although its programs remain in clinical development and have not been approved for commercial use.

BioAge was founded in 2015 and is headquartered in Richmond, California. The company’s operations are centered on research, drug discovery and clinical development, with studies conducted in collaboration with clinical and research organizations. Kristen Fortney, Ph.D., is the company’s co-founder, president and chief executive officer.

View BioAge Labs Profile